Triheptanoin
CAS 620-67-7
Triheptanoin (CAS 620-67-7) is a Phase 4 pharmaceutical compound with 0 bioactivity targets and 15 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Rhabdomyolysis | 22 | 83.528 | 10039020 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| TRIHEPTANOIN | 1313234 | SU | MTHSPL |
| triheptanoin | 1313234 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Triheptanoin used for in pharmaceutical contexts?
Triheptanoin (CAS 620-67-7) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Triheptanoin?
Triheptanoin has 15 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Rhabdomyolysis, Acute coronary syndrome, Acute myocardial infarction, Cardiomyopathy, Death. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Triheptanoin also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Triheptanoin with EU status "permitted".
What clinical phase is Triheptanoin in?
Triheptanoin is rendered with ChEMBL max phase 4 (approved).